Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Roche is extending its Ionis partnership with a new licensing pact for two early-stage RNA-targeted programs in Alzheimer's disease and Huntington's disease,…
Roche has signed another deal with Ionis Pharmaceuticals to license two early-stage RNA-targeted programs for Alzheimer's disease and Huntington's disease,…
Ionis earned a $50 million milestone from Roche for a Phase 1 Alzheimer's trial (CFO Elizabeth L. Hougen).
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Roche licensed two early-stage RNA-targeted programs from Ionis for Alzheimer's and Huntington's disease. Ionis received $60M upfront with eligibility for up to ~$700M in development, regulatory and commercial milestones plus tiered royalties. Ionis advances preclinical work; Roche leads clinical development and commercialization. By Q4 2025 the Alzheimer's program had advanced from preclinical into a Phase 1 trial, triggering a $50M development milestone to Ionis (disclosed on Ionis's Q4 2025 earnings call) and marking the first clinical-stage progress under the partnership.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| F. Hoffmann-La Roche AG / Ionis Pharmaceuticals, Inc. (this deal) | 2023 | $760M | — |
| F. Hoffmann-La Roche AG / Tensha Therapeutics, Inc. | 2016 | $535M | 20 |
| F. Hoffmann-La Roche AG / Manifold Bio, Inc. | 2025 | $2.0B | — |
| F. Hoffmann-La Roche AG / Qyuns Therapeutics Co., Ltd. | 2025 | $1.1B | — |
| F. Hoffmann-La Roche AG / MediLink Therapeutics (Suzhou) Co., Ltd. | 2026 | $570M | — |
| F. Hoffmann-La Roche AG / Hansoh Pharmaceutical Group Co. Ltd. | 2025 | $1.5B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
← Browse all deals · How we score deals
More: 2023 deals · F. Hoffmann-La Roche AG deals · Neurology deals